drugset / Trial / NCT04352803

Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease

NCT04352803 ↗

Phase 1 Unknown 20 enrolled Regeneris Medical
Non-randomizedSequentialOpen-labelTreatment

Summary

The aim of this study is to evaluate the safety and efficacy of autologous adipose-derived mesenchymal cells for treating confirmed or suspected patients with SARS-CoV-2 and compromised respiratory function requiring hospitalization. The hypothesis of the Study is autologous adipose-derived mesenchymal cells given IV to eligible patients will improve clinical outcomes of COVID 19 positive patients with severe pneumonia or ARDS by reducing or avoiding cytokine storm.

Timeline

Start
2020-04
Primary completion
2024-04
Completion
2026-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Adipose MSC's Cell therapy 500000 cells/kg Intravenous